20/20 Biolabs Inc. (AIDX) vs Evogene Ltd. (EVGN)
A side-by-side comparison of 20/20 Biolabs Inc. and Evogene Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AIDX
20/20 Biolabs Inc.
$0.34HealthcareDelayed quote: Oct 6, 2026, 10:46 AM EDT
EVGN
Evogene Ltd.
$0.40HealthcareDelayed quote: Oct 6, 2026, 10:49 AM EDT
Total return — AIDX vs EVGN
growth of $100 · dividends reinvested · last 1yAIDX -98.5% (-98.5%/yr)EVGN -54.5% (-54.5%/yr)EVGN compounded faster over this window
Log scale — wide-divergence pair
AIDX EVGN
AIDX vs EVGN: by the numbers
- •AIDX is the larger company ($4M vs $3M market cap).
- •Both run net losses; AIDX's is the smaller (-285.00% vs -694.19% net margin).
- •EVGN grew revenue faster over the past five years (2.86% vs -2.58% CAGR).
Metrics side by side
Valuation
| Metric | AIDX | EVGN |
|---|---|---|
| P/S ratio | 2.06 | 2.65 |
| P/B ratio | 2.60 | N/A |
Profitability
| Metric | AIDX | EVGN |
|---|---|---|
| Gross margin | 31.52% | -6.25% |
| Operating margin | -162.87% | -364.24% |
| Net margin | -285.00% | -694.19% |
| ROE | -184.04% | N/A |
| ROIC | -116.89% | -130.12% |
Growth (annualized)
| Metric | AIDX | EVGN |
|---|---|---|
| Revenue CAGR (5Y) | -2.58% | 2.86% |
| Total return CAGR (5Y) | N/A | -56.46% |
Frequently asked
- Which has grown faster, AIDX or EVGN?
- Over the past five years, EVGN grew revenue faster — AIDX at a -2.58% CAGR versus EVGN at 2.86%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.